https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-08-23 / Toxicol Appl Pharmacol 2021 Oct;429:115699
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-08-23 / Toxicol Appl Pharmacol 2021 Oct;429:1156992021-08-23 00:00:002021-08-23 00:00:00Targeting CD166 lung cancer stem cells: Molecular study using murine dendritic cell vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-08-01 / Am J Cancer Res 2018;8(8):1514-1527
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-08-01 / Am J Cancer Res 2018;8(8):1514-15272018-08-01 00:00:002018-08-01 00:00:00Oncolytic Newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-16 / Pharmacol. Ther. 2015 Sep;153:1-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-16 / Pharmacol. Ther. 2015 Sep;153:1-92015-05-16 00:00:002019-02-15 08:35:17Vaccine immunotherapy in lung cancer: Clinical experience and future directions
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3062)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3062)2014-06-01 00:00:002014-06-01 00:00:00γδ T cells in combination with Newcastle disease virus and dendritic cell therapy as a novel immunotherapeutic approach in treating of advanced lung cancer.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-02-01 / Transl Lung Cancer Res 2014 Feb;3(1):34-45
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-02-01 / Transl Lung Cancer Res 2014 Feb;3(1):34-452014-02-01 00:00:002014-02-01 00:00:00Immunotherapy prospects in the treatment of lung cancer and mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-02-01 / Transl Lung Cancer Res 2014 Feb;3(1):53-63
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-02-01 / Transl Lung Cancer Res 2014 Feb;3(1):53-632014-02-01 00:00:002019-02-15 08:35:18Immunotherapy in lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-04-16 / Cancer Immunol. Immunother. 2013 May;62(5):909-18
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-04-16 / Cancer Immunol. Immunother. 2013 May;62(5):909-182013-04-16 00:00:002019-02-15 08:48:36Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-06-01 / Expert Opin Biol Ther 2010 Jun;10(6):983-91
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-06-01 / Expert Opin Biol Ther 2010 Jun;10(6):983-912010-06-01 00:00:002019-02-15 08:48:35INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-02-01 / Clin. Cancer Res. 2006 Feb;12(3 Pt 1):878-87
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-02-01 / Clin. Cancer Res. 2006 Feb;12(3 Pt 1):878-872006-02-01 00:00:002019-02-15 08:48:35Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer
